Elizabeth Evans to Cohort Studies
This is a "connection" page, showing publications Elizabeth Evans has written about Cohort Studies.
Connection Strength
0.320
-
Evans E, Li L, Min J, Huang D, Urada D, Liu L, Hser YI, Nosyk B. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction. 2015 Jun; 110(6):996-1005.
Score: 0.075
-
Anglin MD, Nosyk B, Jaffe A, Urada D, Evans E. Offender diversion into substance use disorder treatment: the economic impact of California's proposition 36. Am J Public Health. 2013 Jun; 103(6):1096-102.
Score: 0.066
-
Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019. Drug Alcohol Depend. 2024 Sep 01; 262:111392.
Score: 0.036
-
Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes. JAMA Netw Open. 2024 03 04; 7(3):e242732.
Score: 0.035
-
Wang L, Min JE, Krebs E, Evans E, Huang D, Liu L, Hser YI, Nosyk B. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy. 2017 11; 49:32-40.
Score: 0.022
-
Krebs E, Urada D, Evans E, Huang D, Hser YI, Nosyk B. The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California. Addiction. 2017 May; 112(5):838-851.
Score: 0.021
-
Nosyk B, Min JE, Evans E, Li L, Liu L, Lima VD, Wood E, Montaner JS. The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. Clin Infect Dis. 2015 Oct 01; 61(7):1157-65.
Score: 0.019
-
Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. 2015 Mar-Apr; 23(2):76-89.
Score: 0.019
-
Gill KE, Evans E, Kayser J, Ben-David S, Messinger J, Bruder G, Malaspina D, Corcoran CM. Smell identification in individuals at clinical high risk for schizophrenia. Psychiatry Res. 2014 Dec 15; 220(1-2):201-4.
Score: 0.018
-
Ettner SL, Huang D, Evans E, Ash DR, Hardy M, Jourabchi M, Hser YI. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"? Health Serv Res. 2006 Feb; 41(1):192-213.
Score: 0.010